Ramzi Tabbalat, MD, FACC, FSCCT, Abdali Medical Center, Amman, Jordan, comments on the prevalence of wild-type and mutant ATTR amyloidosis in Jordan and around the world, and comments on current and emerging management strategies for this disease. Dr Tabbalat first emphasizes the importance of family screening and early treatment in patients with mutant ATTR amyloidosis, and outlines the different treatment options for this disease, including tafamidis in patients with cardiac involvement, and TTR stabilizers and silencers in patients with cardiac and neurologic involvement. This interview took place at the 2022 International Symposium on Amyloidosis (ISA) held in Heidelberg, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.